Carlos Solano
A5075722788- Hematopoietic Stem Cell Transplantation
- Cytomegalovirus and herpesvirus research
- Herpesvirus Infections and Treatments
- Immune Cell Function and Interaction
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Polyomavirus and related diseases
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- SARS-CoV-2 and COVID-19 Research
- Parvovirus B19 Infection Studies
- Renal Transplantation Outcomes and Treatments
- Antifungal resistance and susceptibility
- COVID-19 Clinical Research Studies
- T-cell and B-cell Immunology
- Neutropenia and Cancer Infections
- Chronic Myeloid Leukemia Treatments
- Viral-associated cancers and disorders
- Fungal Infections and Studies
- Virus-based gene therapy research
- Multiple Myeloma Research and Treatments
- Animal Virus Infections Studies
- Immunodeficiency and Autoimmune Disorders
- Respiratory viral infections research
Hospital Clínico Universitario de Valencia
2016-2025
Universitat de València
2016-2025
INCLIVA Health Research Institute
2016-2025
Hospital Regional Universitario de Málaga
2024
European Society for Blood and Marrow Transplantation
2011-2023
University of Gothenburg
2012-2020
Grupo Español de Trasplante Hematopoyético y Terapia Celular
2020
Hudson Institute
2019
Merck Institute for Science Education
2019
John Wiley & Sons (United States)
2019
Chronic graft-versus-host disease (GVHD) is the leading cause of later illness and death after allogeneic hematopoietic stem-cell transplantation. We hypothesized that inclusion antihuman T-lymphocyte immune globulin (ATG) in a myeloablative conditioning regimen for patients with acute leukemia would result significant reduction chronic GVHD 2 years peripheral-blood transplantation from an HLA-identical sibling.We conducted prospective, multicenter, open-label, randomized phase 3 study ATG...
Summary Antifungal prophylaxis for allogeneic haematopoietic stem‐cell transplant (alloHCT) recipients should prevent invasive mould and yeast infections (IFIs) be well tolerated. This prospective, randomized, open‐label, multicentre study compared the efficacy safety of voriconazole (234 patients) versus itraconazole (255 in alloHCT recipients. The primary composite endpoint, success prophylaxis, incorporated ability to tolerate drug ≥100 d (with ≤14 interruption) with survival day 180...
<h3>Importance</h3> Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster. <h3>Objective</h3> To assess the efficacy and adverse event profile of in immunocompromised HSCT recipients. <h3>Design, Setting, Participants</h3> Phase 3, randomized, observer-blinded study conducted 167 centers 28...
Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined.This was a Spanish transplant group cell therapy (GETH) multicenter retrospective observational study, which included large cohort blood cancer laboratory-confirmed SARS-CoV-2 infection through PCR assays from March 1st 2020 to May 15th 2020.We 367 pediatric adult malignancies, including recipients autologous (ASCT) (n = 58) or allogeneic stem transplantation (allo-SCT) 65) 41...
Abstract Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with best overall response rate (ORR) and complete (CR) in infused patients 52% 40%, respectively. We report outcomes tisa‐cel standard‐of‐care (SOC) setting R/R LBCL. Data from all LBCL who underwent leukapheresis December 2018...
Summary. We have analysed the incidence and risk factors for occurrence of invasive fungal infections (IFI) among 395 recipients an allogeneic peripheral blood stem cell transplantation (PBSCT) from a human leucocyte antigen (HLA)‐identical sibling. IFI ( n = 50) occurred in 46 patients, giving overall probability 14%. There were 12 cases candidiasis (3%), with only one death. Non‐ Candida 37 patients (12% probability), mostly aspergillosis 32). In multivariate analysis two significant...
Background. The benefit of the combination serum galactomannan (GM) assay and polymerase chain reaction (PCR)–based detection Aspergillus DNA for early diagnosis therapy invasive aspergillosis (IA) in high-risk hematological patients remains unclear.
This is a multicenter prospective observational study that included large cohort (n = 397) of allogeneic (allo-HSCT; 311) and autologous (ASCT) hematopoietic stem cell transplant 86) recipients who were monitored for antibody detection within 3-6 weeks after complete severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from February 1, 2021, to July 20, 2021. Most patients 387, 97.4%) received mRNA-based vaccines. the (93%) vaccinated more than 1 year transplant....
Abstract The long-term clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological has been little explored. A prospective multicenter registry-based cohort study conducted from December 2020 July 2022 by the Spanish Transplant and Cell Therapy group, was used analyze relationship over time after full vaccination (at 3–6 weeks, 3, 6 12 months) (2 doses) booster doses with breakthrough infection 1551 disorders. At a median...
Neutropenia may limit the use of valganciclovir treatment for cytomegalovirus (CMV) infection following hematopoietic cell transplant (HCT). A phase 2 study indicated efficacy maribavir with fewer treatment-limiting toxicities than valganciclovir.
Immune effector cell-associated neurotoxicity syndrome (ICANS) is common after chimeric antigen receptor T-cell (CAR-T) therapy. Objective. This study aimed to assess the impact of preinfusion electroencephalography (EEG) abnormalities and EEG findings at ICANS onset for predicting risk severity in 56 adult patients with refractory lymphoma undergoing CAR-T Study design. EEGs were conducted time lymphodepleting chemotherapy shortly ICANS. Results. Twenty-eight (50%) developed a median 6 days...
Abstract Brexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed or refractory mantle lymphoma (r/r MCL), but the optimal choice remains unclear. We conducted an analysis of 64 r/r MCL patients aged ≥50 years treated with brexu-cel in ZUMA-2 study, matching them 1:1 by propensity score to (out 272) who underwent alloHCT using data from EBMT registry. Median follow-up time was 36.5 34.1 months matched cohort,...
ABSTRACT The performance of a plasma real-time PCR (cytomegalovirus [CMV] kit; Abbott Diagnostics) was compared with that the antigenemia assay for surveillance active CMV infection in 42 allogeneic hematopoietic stem cell transplantation (Allo-SCT) recipients. A total 1,156 samples were analyzed by two assays. Concordance between assays 82.2%. Plasma DNA levels correlated number pp65-positive cells, particularly prior to initiation preemptive therapy. Fifty-seven episodes detected 37...
There is limited information on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell immune responses in patients with disease 2019 (COVID-19). Both CD4+ and CD8+ T cells may be instrumental resolution of protection from SARS-CoV-2 infection. Here, we tested 25 hospitalized either microbiologically documented COVID-19 (n = 19) or highly suspected having the 6) for presence SARS-CoV-2-reactive CD69+ expressing interferon-γ (IFN-γ) producing using flow-cytometry intracellular...
Syndrome coronavirus 2 (SARS-CoV-2) pandemic is causing a second outbreak significantly delaying the hope for virus’ complete eradication. In absence of effective vaccines, we need treatments with low adverse effects that can treat hospitalized patients COVID-19 disease. this study, determined existence SARS-CoV-2-specific T cells within CD45RA – memory in blood convalescent donors. Memory respond quickly to infection and provide long-term immune protection reduce severity symptoms. Also,...
Abstract Background The clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological has not yet been established. Patients and methods A prospective multicenter registry-based cohort study conducted from December 2020 2021 by the Spanish transplant cell therapy group was used analyze relationship at 3–6 weeks after full vaccination (2 doses) with breakthrough infection 1394 disorders. Results At a median follow-up 165 days...